Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

PharmaShots Interview Tillotts Pharma’s Adrian Hill & Christian Weidenfeller Share Insights on Dificlir (fidaxomicin) for the Treatment of Clostridioides Difficile Infection
PharmaShots Interview: Tillotts Pharma’s Adrian Hill & Christian Weidenfeller Share Insights on Dificlir (fidaxomicin) for the Treatment of Clostridioides Difficile Infection
In an interview with PharmaShots, Adrian Hill, Head of Commercial Operations & Christian Weidenfeller, Global Head of Medical Affairs Anti-Infectives at Tillotts Pharma share their views on the ESCMID recommendation for Dificlir (fidaxomicin) to treat Clostridioides Difficile Infection Shots: ·        Clostridioides difficile infection (CDI) is the leading cause of hospital-acquired infection · …
March 21, 2022
PharmaShots Interview Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof
PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof
In an interview with PharmaShots, Philip Brown, Chief Medical Officer at Dermavant share his views on the data of Tapinarof in the P-III (PSOARING 3) study for the treatment of Plaque Psoriasis & highlights new patient satisfaction data Shots: The P-III (PSOARING 3) extension study evaluates tapinarof (1%, qd) in adult patients with PsO for ~40wks. & a 4wks. safety follow-up period The…
March 15, 2022
PharmaShots Interview Jazz Pharmaceuticals’ Bruce C. Cozadd Shares Insight on Vision 2025 During the Virtual Presentation at 40th Annual J.P. Morgan Healthcare Conference 2022
PharmaShots Interview: Jazz Pharmaceuticals’ Bruce C. Cozadd Shares Insight on Vision 2025 During the Virtual Presentation at 40th Annual J.P. Morgan Healthcare Conference 2022
In an interview with PharmaShots, Bruce C. Cozadd, Chairman and Chief Executive Officer at Jazz Pharmaceuticals shared his views on Vision 2025 to deliver sustainable growth and enhanced value Shots: The company reported Vision 2025 to deliver sustainable growth and enhanced value to drive the transformation to an innovative, high-growth, global biopharmaceutical leader The company is expected to…
March 14, 2022
PharmaShots Interview Guardant Health’s Kathryn Lang Shares Insight on SHIELD Blood Test for Colorectal Cancer
PharmaShots Interview: Guardant Health’s Kathryn Lang Shares Insight on SHIELD Blood Test for Colorectal Cancer
In an interview with PharmaShots, Kathryn Lang, Vice President, Outcomes & Evidence at Guardant Health shared her views on the enrolment of the final patient in the (ECLIPSE) trial for SHIELD blood test to treat Colorectal Cancer Shots: The company has reported the patient enrolment in the (ECLIPSE) trial to evaluate SHIELD blood test in 12750 patients aged 45-84yr. with colorectal…
March 9, 2022
PharmaShots Interview SalioGen Therapeutics’ Ray Tabibiazar Shares Insights on Gene Coding Platform
PharmaShots Interview: SalioGen Therapeutics’ Ray Tabibiazar Shares Insights on Gene Coding Platform
In an interview with PharmaShots, Ray Tabibiazar, M.D., Chief Executive Officer and Chairman, Board of Directors at SalioGen Therapeutics shares his views on the completion of $115M series B financing to advance gene coding platform for genetic diseases Shots: The company has completed $115M series B financing which was co-led by GordonMD global investments and EPIQ capital group. The financing will…
March 8, 2022
PharmaShots Interview: Clario’s Joyce Suhy Shares Insights on PET Imaging Clinical Trials
In an interview with PharmaShots, Joyce Suhy, Senior Vice President, Medical Imaging at Clario shares her views on the PET imaging clinical trials & expands its 2018 collaboration with XingImaging for Alzheimer’s disease and other neurodegenerative diseases Shots: Clario & XingImaging have expanded the collaboration to provide PET imaging clinical trials for neurodegenerative therapeutics in China. The initial study used Amyvid (florbetapir) PET imaging to…
March 1, 2022
PharmaShots Interview Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis
PharmaShots Interview: Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis
In an interview with PharmaShots, Jonathan Wang, Executive Vice President and Head of Business Development at Zai Lab shares his views on the license agreement with Karuna Therapeutics for KarXT (xanomeline-trospium) to treat schizophrenia and psychosis Shots: The companies collaborate to develop, manufacture & commercialize KarXT in Greater China including mainland China, Hong Kong, Macau & Taiwan Zai Lab gets exclusive rights to develop &…
February 28, 2022
Viewpoints_Senior Editor
PharmaShots Interview: Boston Scientific’s Ron Morton Shares Insights on the Rezūm Water Vapor Therapy
In an interview with PharmaShots, Ron Morton, Chief Medical Officer, Vice President of Medical Affairs, UroPH at Boston Scientific shares his views on Rezūm Water Vapor Therapy to reduces the size of the prostate and provides lasting symptom relief from benign prostatic hyperplasia Shots: The company reported the new data from a survey of 2,000 American men aged ≥60 conducted by…
February 24, 2022
Viewpoints_Tania Small
PharmaShots Interview: GSK’s Tania Small Shares Insight on Target the Future Program
In an interview with PharmaShots, Tania Small, Vice President of Global Medical Oncology at GSK shares her views on the launch of Target the Future Program to help address the challenges affecting the multiple myeloma community Shots: The company has launched Target the Future program to educate people in the field of multiple myeloma and address unmet needs in the community A grant of…
February 23, 2022
Load more